This is Great for HTDS.
November 09, 2004 04:00 PM US Eastern Timezone
Breast Cancer Treatment Introduced at Conference by ArTec
RENO, Nev.--(BUSINESS WIRE)--Nov. 9, 2004--ArTec, Inc., (Pink Sheets:ATKJ) introduced its revolutionary cancer treatment Immunostimulant Tubercin at the 2004 spring meeting of Korean Breast Cancer Society. Dr. Tai Ho Chung (ArTec) made the presentation together with a research team from Kyungpook National University Hospital Daegu, South Korea. The team presented research data demonstrating that Tubercin when combined with conventional cancer treatment such as chemotherapy and other drug therapies promulgated by leading pharmaceutical companies, increases "the efficacy of these treatments by several times in the treatment of breast cancer." Tubercin also proved effective in mitigating certain well-documented side effects of established treatment methods such as leucocytopenia, a deficiency of white blood cells, and peripheral neuritis, an inflammation of the nerves in the arms and legs. Dr. Chung's presentation stated, "We have significant clinical experience that Tubercin can improve leucocytopenia induced by chemo-radio therapy...and other cancer treatments."
ArTec notes that the Korean scientific community considers Tubercin as an alternative or ancillary method to conventional treatments, given the prevalence of breast cancer in Korea. Data collected in a study involving 38 medical schools in South Korea demonstrated a high increase in the number of breast cancer patients and incidence rates. A recent book recently published in Japan, entitled "Immunological Revolution," states, "that when patients with terminal cancer opted for immunotherapy versus chemo-radio therapy, they had a longer life span," a conclusion that supports ArTec's thesis.
Dr. Chung's research team concluded in its presentation to the Breast Cancer Society that Tubercin was not only effective in mitigating commonly occurring side-effects of widely used treatment modalities but, also showed great promise as a preventative treatment by performing a function known as "immunosurveillance" that essentially keeps cancer-fighting T-cells healthy.
Forward-looking statements in this press release, the company cautions the investors, involve risks and uncertainties pursuant to the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. In addition, the company cautions investors that it undertakes no obligations or responsibilities to publicly update these forward-looking statements to reflect Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events.
